Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?

Current treatment options in oncology - 1 Jul 2023

Schwab Robert D, Luger Selina M

Abstract excerpt

OPINION STATEMENT: In patients with chronic myeloid leukemia who require second-line tyrosine kinase inhibitor therapy, many options exist. These treatments include alternate generation tyrosine kinase inhibitors and in some cases consideration of allogeneic transplant. Although efficacious, each tyrosine kinase inhibitor possesses distinct side effects and pharmacological profiles that prevent a generalizable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 37119409
DOI: 10.1007/s11864-023-01088-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?PMID 37119409Read ↗

Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.Semantic proximity Read ↗

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Semantic proximity Read ↗

Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Semantic proximity Read ↗

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read ↗

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Semantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Is there a best TKI for chronic phase CML?Semantic proximity Read ↗

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.